CYP2D6 and myocardial infarction: In a study of post-MI patients, we demonstrated a six-fold variation in metoprolol plasma trough concentrations between genotypes, accompanied by an attenuation in achieved maximum heart rate among patients encoding strongly decreased or absent CYP2D6 metabolism vs. those expressing normal CYP2D6 metabolism [17].